Source: Pharamceutical Technology

Imstem: IMS-001 by Imstem Biotechnology for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval

IMS-001 is under clinical development by Imstem Biotechnology and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS).

Read full article »

Imstem's Competitors | Imstem's News | Imstem's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Rami Levin

CEO Approval Rating

90/100

Imstem is a Connecticut-based biotechnology company that develops and commercializes stem cell based regenerative cellular therapies for the treatment of serious diseases.